- Home
- ABSI vs VSTM Comparison
ABSI vs VSTM Comparison
Compare ABSI & VSTM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ABSI
- VSTM
- Stock Information
- Founded
- ABSI 2011
- VSTM 2010
- Country
- ABSI United States
- VSTM United States
- Employees
- ABSI N/A
- VSTM N/A
- Industry
- ABSI Biotechnology: Pharmaceutical Preparations
- VSTM Biotechnology: Pharmaceutical Preparations
- Sector
- ABSI Health Care
- VSTM Health Care
- Exchange
- ABSI Nasdaq
- VSTM Nasdaq
- Market Cap
- ABSI 353.8M
- VSTM 313.1M
- IPO Year
- ABSI 2021
- VSTM 2012
- Fundamental
- Price
- ABSI $3.09
- VSTM $5.74
- Analyst Decision
- ABSI Strong Buy
- VSTM Strong Buy
- Analyst Count
- ABSI 5
- VSTM 9
- Target Price
- ABSI $8.40
- VSTM $13.13
- AVG Volume (30 Days)
- ABSI 3.4M
- VSTM 902.1K
- Earning Date
- ABSI 05-13-2025
- VSTM 05-08-2025
- Dividend Yield
- ABSI N/A
- VSTM N/A
- EPS Growth
- ABSI N/A
- VSTM N/A
- EPS
- ABSI N/A
- VSTM N/A
- Revenue
- ABSI $4,534,000.00
- VSTM $10,000,000.00
- Revenue This Year
- ABSI $156.33
- VSTM $7.68
- Revenue Next Year
- ABSI $93.61
- VSTM $605.06
- P/E Ratio
- ABSI N/A
- VSTM N/A
- Revenue Growth
- ABSI N/A
- VSTM N/A
- 52 Week Low
- ABSI $2.01
- VSTM $2.10
- 52 Week High
- ABSI $6.33
- VSTM $13.52
- Technical
- Relative Strength Index (RSI)
- ABSI 54.32
- VSTM 51.60
- Support Level
- ABSI $2.95
- VSTM $4.69
- Resistance Level
- ABSI $3.30
- VSTM $5.12
- Average True Range (ATR)
- ABSI 0.28
- VSTM 0.55
- MACD
- ABSI 0.12
- VSTM -0.02
- Stochastic Oscillator
- ABSI 83.85
- VSTM 70.35
About ABSI Absci Corporation
Absci Corp is the Artificial intelligence powered synthetic biology company unlocking the potential of proteins as the next generation of therapeutics. It enables the creation of novel biologics by unifying biologic drug discovery and cell line development into one simultaneous process.
About VSTM Verastem Inc.
Verastem Inc is late-stage development biopharmaceutical company, committed to advancing new medicines for patients battling cancer. Its pipeline is focused on novel anticancer agents that inhibit critical signaling pathways in cancer that promote cancer cell survival and tumor growth, particularly RAF/MEK inhibition and FAK inhibition.